Reinicke C, Clemens M, Steiner A, Stiller K J, Tanner E, Wächter G
Institut für Pharmakologie und Toxikologie, Friedrich-Schiller-Universität Jena.
Z Gesamte Inn Med. 1988 Feb 15;43(4):80-3.
By means of the aminopyrine breath analysis the influence of phenylbutazone, propyphenazone and of the combination preparation Wofapyrin "new" on the aminopyrine-N-demethylation, a hepatic microsomal performance of biotransformation in patients with diseases of the rheumatic circle of forms was examined. The enzyme-inducing effect of phenylbutazone known from literature could be confirmed. On the other hand despite a relatively highly dosed one-week treatment propyphenazone did not lead to changes of the demethylation capacity of the liver in the majority of the patients. In individual cases increases of the capacity are possible. In general, however, the doses of propyphenazone usual in the practice for the treatment of acute feverish infections no disturbing effects of induction or inhibition on the metabolic liver functions represented by the amino-N-demethylation are to be expected. The enzyme-inducing effect of Wofapyrin "new" is to be ascribed to the phenyl-butazone component.
通过氨基比林呼吸分析，研究了保泰松、安乃近以及复方制剂“新渥发哌啉”对氨基比林 -N -去甲基化的影响，氨基比林 -N -去甲基化是一种肝微粒体生物转化功能，在患有风湿性疾病的患者中进行了此项研究。文献中已知的保泰松的酶诱导作用得到了证实。另一方面，尽管进行了为期一周的相对高剂量治疗，但在大多数患者中，安乃近并未导致肝脏去甲基化能力的改变。个别情况下，能力可能会增加。然而，一般来说，在治疗急性发热性感染的实际应用中，常用剂量的安乃近预计不会对以氨基 -N -去甲基化表示的肝脏代谢功能产生诱导或抑制的干扰作用。“新渥发哌啉”的酶诱导作用应归因于保泰松成分。
